To discover how different forms of radiation affect the sleep, mood, and social function of adults with brain cancer. Doctors have suspected that these patients may be getting worse sleep, but no one has studied it. Since sleep is important in recovery and overall body function, understanding how radiation changes it will lead to a greater clinical understanding of the treatment.

The purpose of this study is to develop and validate an Artificial intelligence (AI)-based tissue sample analysis tool that can predict response & progression rates to chemotherapy in intermediate-risk (IR) and high-risk (HR) Non-muscle invasive bladder cancer (NMIBC) patients. This study will use AI-based tissue sample analysis as a possible tool to help predict which patients are at high-risk for cancer recurrence and progression after surgery and chemotherapy treatment. Specimens will be obtained for each patient before treatment and at the 12, 24, & 36 month follow-up to be analyzed using the AI-based tool.

This study will evaluate the safety and tolerability of EG 70, a gene therapy, which is given inside the bladder, and its effectiveness on eliminating bladder tumors in patients with NMIBC who have failed BCG therapy and have been recommended to have their bladder removed. Giving the study drug inside the bladder is to expose cells in the lining of the bladder, including your cancerous cells, to genes that may cause an immune response inside the bladder and kill the tumor cells.

Aim 1: To co-develop the "Patient-Centered Pharmacy Pathway for Oral Chemotherapy" (P3OC) components through stakeholder engagement by conducting a modified Delphi panel with pharmacists, physicians, and other oncology healthcare providers (36,37) to determine key symptoms to assess during oral chemotherapy. Aim 2: To conduct usability testing(38,39) of the P3OC EHR Smart Form, verbal PROM, and report/dashboard with pharmacists.

This project is a randomized clinical trial (study that randomly assigns participants to one arm to fairly understand outcomes) that aims to assess if information from gene expression classifier (GEC) testing is helpful for both patients and their doctors in the management of care for newly diagnosed prostate cancer patients.

Our team developed a calculator to help oncologists better estimate prognosis in patients with metastatic breast cancer (MBC). Using this information, our team developed a prognostic calculator to predict risk of death within 30 days for patients with MBC. For this information to impact care, it will have to be used in clinical practice. In order to increase the likelihood of successful adoption of the calculator into clinical practice, we will study its implementation and evaluate its impact. In this study, we will seek the input of doctors, nurses, and advance practice providers who care for patients with MBC to better understand the factors that encourage and dissuade discussion of prognosis and use of such a prognostic tool.

Purpose:This is a two-arm preliminary efficacy RCT in 120 participants testing a 6-week home-based walking and progressive resistance exercise program (EXCAP©®) vs. standard care on CIPN, interoception, and inflammation. Participants: This study will enroll 120 participants receiving neurotoxic chemotherapy or have completed neurotoxic chemotherapy in the past nine months (i.e., taxane-, platinum-, vinca alkaloid-, epothilone-, or proteasome inhibitor-based chemotherapy). Procedures (methods): Participants will complete questionnaires, clinical assessments, and a blood draw at two time points: pre-intervention (week 0, T1) and post-intervention (approximately week 6, T2).

This is a study to assess patient, provider, and pharmacist perceptions of delivering FIT kits for colorectal cancer screening in pharmacy settings.

Develop a device to measure patient preferences in the treatment of bladder cancer.

The aim of this study for low and standard risk germ cell tumor (GCT) patients is to minimize toxicity by reducing therapy while maintaining current survival rates. The trial will eliminate chemotherapy for low risk patients who are likely cured with surgery and will observe the salvage rates among those who recur.